Jim Cramer has picked up on a pattern when it comes to biotech stocks that could change the game for an investor's portfolio—listen to the darned CEO interviews.
In fact, Cramer would argue that the biotech group has gone from being hit or miss to being totally predictable just based on what the CEOs are saying on "Mad Money."
For instance, BioMarin racked up a 12 percent gain after a successful trial of a drug that combats dwarfism in children. The results of the trial triggered price target bumps from all of the research houses that follow the stock.
Cramer was shocked when he saw this. Not because of the results of the study, but the fact that these results seemed to be much of a surprise in the first place. BioMarin CEO J.J. Bienaime said many times on the show that things looked good for this test and that he was hopeful. And while his demeanor came across as understated and nonpromotional, these results should have been no surprise to anyone who watched "Mad Money."